Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | RHEB | Q15382 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7385067 | 0.87 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7708759 | 0.85 | KMT2A (0.52) | CA1CA2CA12CA9CA14 | |
| SCHEMBL7588248 | 0.85 | ALDH1A1 (0.55) | CA1CA2CA12CA9CA14 | |
| SCHEMBL109451 | 0.84 | CA1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL16617577 | 0.83 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL1019092 | 0.83 | CA1 (0.50) | CA1CA2CA12CA9CA14 | |
| SCHEMBL8562574 | 0.83 | CYP4A11 (0.49) | CA1CA2CA12CA9CA14 | |
| SCHEMBL14344637 | 0.82 | LOXL2 (0.41) | CA1CA2CA12CA9CA14 | |
| SCHEMBL27864995 | 0.82 | ALDH1A1 (0.61) | CA1CA2CA12CA9CA14 | |
| SCHEMBL12900838 | 0.81 | CA1 (0.49) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11352321-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-10-31 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-20190099391-A1 | Glucagon Antagonists | LIGAND PHARMACEUTICALS, INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221130-B2 | Glucagon antagonists | METABASIS THERAPEUTICS, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| EP-3153501-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-10076504-B2 | Glucagon antagonists | LIGAND PHARMACEUTICALS, INC. | 2018-09-18 | — | — | US | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2799428-A2 | Glucagon antagonists | Metabasis Therapeutics, Inc. (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2326618-B1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130030029-A1 | Glucagon Antagonists | METABASIS THERAPEUTICS, INC. (US) | 2013-01-31 | — | — | US | disclosed |
| EP-2326618-A1 | GLUCAGON ANTAGONISTS | Metabasis Therapeutics, Inc. (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
| WO-2010019830-A1 | GLUCAGON ANTAGONISTS | METABASIS THERAPEUTICS, INC. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030029-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | CA1 2435/4885CA2 941/4885CA12 3362/4885 |
| US-20190330144-A1 | GLUCAGON ANTAGONISTS | GLP1R, GCG, GCGR | CA1 2435/4885CA2 941/4885CA12 3362/4885 |
| US-20190099391-A1 | Glucagon Antagonists | GLP1R, GCG, GCGR | CA1 2363/4885CA2 926/4885CA12 3385/4885 |
| US-10076504-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | CA1 2363/4885CA2 926/4885CA12 3385/4885 |
| US-11352321-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | CA1 2435/4885CA2 941/4885CA12 3362/4885 |
| US-10221130-B2 | Glucagon antagonists | GLP1R, GCG, GCGR | CA1 2363/4885CA2 926/4885CA12 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.